NCT03683719 - Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema | Biotech Hunter

Enrollment

258

Participants

Timeline

Start Date

November 28, 2018

Primary Completion Date

March 6, 2020

Study Completion Date

April 20, 2020

Conditions

Chronic Hand Eczema

Interventions

DRUG

Delgocitinib cream

Cream for topical application.

DRUG

Delgocitinib cream vehicle

The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.

Trial Locations (28)

2400

Leo Pharma Investigational Site, Copenhagen

2730

LEO Pharma Investigational Site, Herlev

2900

Leo Pharma Investigational Site, Hellerup

8200

Leo Pharma Investigational Site, Aarhus

10117

Leo Pharma Investigational Site, Berlin

15831

Leo Pharma Investigational Site, Mahlow

23538

Leo Pharma Investigational Site, Lübeck

24105

Leo Pharma Investigational Site, Kiel

24148

Leo Pharma Investigational Site, Kiel

27574

Leo Pharma Investigational Site, Bremerhaven

33012

Leo Pharma Investigational Site, Hialeah

37075

Leo Pharma Investigational Site, Göttingen

40225

Leo Pharma Investigational Site, Düsseldorf

42287

Leo Pharma Investigational Site, Wuppertal

44791

Leo Pharma Investigational Site, Bochum

55101

Leo Pharma Investigational Site, Mainz

56242

Leo Pharma Investigational Site, Selters

70178

Leo Pharma Investigational Site, Stuttgart

70499

Leo Pharma Investigational Site, Stuttgart

80337

Leo Pharma Investigational Site, München

85724

Leo Pharma Investigational Site, Tucson

87700

Leo Pharma Investigational Site, Memmingen

89129

Leo Pharma Investigational Site, Langenau

97223

Leo Pharma Investigational Site, Portland

97239-4501

Leo Pharma Investigational Site, Portland

01307

Leo Pharma Investigational Site, Dresden

07548

Leo Pharma Investigational Site, Gera

07743

Leo Pharma Investigational Site, Jena